Effective drug combinations in breast, colon and pancreatic cancer cells

[1]  Hayley E. Francies,et al.  Cancer research needs a better map , 2021, Nature.

[2]  Peter B. McGarvey,et al.  UniProt: the universal protein knowledgebase in 2021 , 2020, Nucleic Acids Res..

[3]  A. Lægreid,et al.  A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines , 2019, Scientific Data.

[4]  E. Pasquier,et al.  Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data , 2019, Frontiers in chemistry.

[5]  Amir K. Foroushani,et al.  Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen , 2019, Nature Communications.

[6]  Keisha N. Hardeman,et al.  Quantifying Drug Combination Synergy along Potency and Efficacy Axes. , 2019, Cell systems.

[7]  Howard Lightfoot,et al.  Cell Model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models , 2018, Nucleic Acids Res..

[8]  Francesco Iorio,et al.  CELLector: Genomics Guided Selection of Cancer in vitro Models , 2018, bioRxiv.

[9]  J. Montero,et al.  Why do BCL-2 inhibitors work and where should we use them in the clinic? , 2018 .

[10]  Andreas Bender,et al.  DeepSynergy: predicting anti-cancer drug synergy with Deep Learning , 2017, Bioinform..

[11]  Julio Saez-Rodriguez,et al.  GDSCTools for mining pharmacogenomic interactions in cancer , 2017, bioRxiv.

[12]  Elisa Ficarra,et al.  Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer , 2017, Nature Communications.

[13]  Steven J. M. Jones,et al.  CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.

[14]  Juanita Lopez,et al.  Combine and conquer: challenges for targeted therapy combinations in early phase trials , 2017, Nature Reviews Clinical Oncology.

[15]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[16]  Francesco Iorio,et al.  Multilevel models improve precision and speed of IC50 estimates. , 2016, Pharmacogenomics.

[17]  Rafael C. Jimenez,et al.  The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases , 2013, Nucleic Acids Res..

[18]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[19]  G. Weiss,et al.  Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer , 2013, Investigational New Drugs.

[20]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[21]  Elena Baralis,et al.  LAS: A Software Platform to Support Oncological Data Management , 2012, Journal of Medical Systems.

[22]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[23]  M. Garrett,et al.  Anticancer therapy with checkpoint inhibitors: what, where and when? , 2011, Trends in pharmacological sciences.

[24]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .